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ABSTRACT 
CURCUMIN AND ITS OXIDATIVE DEGRADATION PRODUCTS: THEIR 
COMPARATIVE EFFECTS ON INFLAMMATION 
MAY 2016 
 
JULIA ZHU, B.S., CORNELL UNIVERSITY 
M.S., UNIVERSITY OF MASSACHUSETTS AMHERST 
Directed by: Dr. Guodong Zhang  
 
 The anti-inflammatory agent curcumin degrades rapidly, leading to speculations that 
curcumin’s reported effects stem from its degradation products. Curcumin can degrade 
via hydrolysis, and more recently it was discovered that curcumin can degrade via 
oxidation at physiological pH. Additionally, bicyclopentadione is the major degradation 
product from this oxidation reaction. Evidence from the literature suggests that curcumin 
degrades primarily through oxidation. However, the biology of the oxidation products is 
not well characterized, and there is debate on whether oxidation intermediates or 
curcumin itself is more biologically active. To further elucidate the biology of the 
oxidation products, their effects on inflammation were examined. RAW264.7 murine 
macrophage cells were stimulated with E. coli lipopolysaccharide (LPS) and treated with 
curcumin, curcumin’s total oxidative degradation products, and bicyclopentadione. 
Curcumin strongly decreased LPS-induced nitric oxide production and iNOS expression 
in a dose dependent manner; total degradation products slightly decreased nitric oxide 
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production and iNOS expression, while bicyclopentadione failed to decrease either. 
Additionally, curcumin was significantly more effective than either bicyclopentadione or 
total degradation products in inhibiting COX-2 expression. iNOS and COX-2 arise from 
the activation of the NF-kB pathway, which curcumin is known to modulate; thus, the 
oxidation products’ effect on key proteins in this pathway was also examined. Neither 
total degradation products nor bicyclopentadione inhibited translocation of NF-kB into 
the nucleus, prevented degradation of IκBα, nor inhibited phosphorylation of IKK as 
effectively as curcumin. In conclusion, curcumin is significantly more effective at 
inhibiting inflammation than the oxidation degradation products. 
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CHAPTER 1 
LITERATURE REVIEW 
1.1 Introduction 
 Substantial studies have shown that curcumin, a bis-α,β-unsaturated β-diketone 
compound found in turmeric, has potent anti-cancer and anti-metastatic actions 
1
. Indeed, 
many animal studies have shown that curcumin suppressed primary tumor growth of 
many types of cancers, including but not limited to pancreatic cancer 
2
, breast cancer 
3
, 
cervical cancer 
4
, lung cancer 
5
, and colon cancer 
6
. Tumor metastasis, the process by 
which tumor cells spread from the primary tumor site to other organs, causes approximate 
90% of human cancer deaths 
7
. Animal experiments have also shown that curcumin 
inhibited tumor metastasis of prostate cancer 
8-10
, breast cancer 
11-14
, colorectal cancer 
15
, 
and pancreatic cancer 
16
. Human studies also support the cancer risk reducing effects of 
curcumin. In a Phase II clinical trial of colorectal cancer, daily intake of 4 grams of 
curcumin for a month caused a ~40% reduction of aberrant crypt foci 
17
. In another Phase 
II human clinical trial, daily intake of 8 grams of curcumin demonstrated anti-cancer 
efficacy in some patients with advanced pancreatic cancer 
18
. Together, these results 
make curcumin a promising dietary compound for cancer prevention and/or treatment.  
Curcumin inhibits tumor progression and metastasis through multiple possible 
mechanisms. Previous studies demonstrated that curcumin inhibited cancer cell 
proliferation by inducing cell cycle arrest and apoptosis and inhibiting cancer cell 
migration and invasion, which are critical cellular processes involved in tumor 
progression and metastasis 
19
. Curcumin has also been shown to inhibit inflammation by 
suppressing NF-kB signaling and modulating the expressions of inflammatory cytokines 
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and microRNAs in cancer cells, leading to reduced cancer progression and metastasis 
9,10,15,20
. Besides directly targeting cancer cells, curcumin can also target tumor-associated 
endothelial cells, resulting in reduced tumor angiogenesis and associated tumor 
progression and metastasis 
21
. In addition, a recent study showed that curcumin potently 
inhibited lymphangiogenesis (de novo lymphatic formation), which is a critical process in 
mediating tumor metastasis 
22
. In summary, curcumin can inhibit tumor growth and 
metastasis through targeting several critical cellular processed involved in tumorigenesis, 
including cancer cell proliferation and motility, tumor inflammation, angiogenesis and 
lymphangiogenesis.  
Although the cancer risk-reducing effects of curcumin have been well characterized, 
the molecular mechanisms by which curcumin inhibits cancer are not well understood. 
Curcumin has poor metabolic and chemical stability, making it difficult to determine 
whether the observed anti-cancer effects are mediated by curcumin itself or its 
metabolites. Indeed, many studies have shown that curcumin has a poor 
pharmacokinetics profile: one study showed that after a single oral dose of 10 or 12 
grams of curcumin, free form of curcumin was barely detected in human plasma 
23
. The 
low levels of curcumin in circulation make it difficult to understand how curcumin exerts 
systematic anti-cancer effects, particularly in its inhibitory effect on non-gastrointestinal 
tract cancer types. This leads to hypothesis that the biological effects of curcumin are 
mediated by its metabolites. However, many studies have shown that most of the 
enzymatic metabolites of curcumin are either biologically less active or inactive 
compared to curcumin. For example, curcumin sulfate and curcumin glucuronide, which 
are the major metabolites of curcumin after oral consumption, have been shown to have 
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dramatically reduced biological activities 
22,24-26
. These results suggest that the biological 
activities of curcumin are unlikely to be mediated by these enzymatic metabolites. 
Besides its poor metabolic stability, curcumin also has poor chemical stability: it 
rapidly degraded in aqueous solution at physiological pH with a half-life of several 
minutes, leading to rapid formation of various degradation products 
27,28
. These chemical 
degradation products include two classes of compounds: (1) alkaline hydrolysis products, 
where the hydroxyl ion (OH
-
) attacks the carbonyl group of curcumin, generating 
hydrolyzed products such as ferulic acid, vanillin, ferulaldehyde, and feruloyl methane 
29
; 
(2) autoxidation products, where curcumin is first converted to a phenolic radical, which 
then migrates to the conjugated heptadienedione chain and initiates a chain reaction of 
curcumin degradation to generate cyclized compounds such as bicyclopentadione 
27,28,30
. 
Recently, several studies have suggested that the biological activities of curcumin could 
be mediated by its degradation products. In this chapter, the chemistry and biology of the 
curcumin degradation products will be discussed. 
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1.2 Chemistry of alkaline hydrolysis of curcumin  
 Wang et al. discovered that curcumin rapidly degraded in aqueous solution (e.g. 
phosphate, citrate-phosphate, carbonate buffers and serum-free cell culture medium) in a 
pH-dependent manner: in acidic environments (pH = 3-6.5), the half-life of curcumin in 
aqueous buffer was around 100-200 min, while at neutral and alkaline environments (pH 
>7), the half-life of curcumin was around 10 min. HPLC analysis showed that the 
degradation products included vanillin, ferulic acid, ferulic aldehyde, feruloyl methane, 
and trans-6-(4'-hydroxy-3'-methoxyphenyl)-2,4-dioxo-5-hexenal 
29,31
, which are break-
down products of curcumin. Together, these results suggest that these degradation 
products are formed through a hydroxyl ion (OH
-
)-dependent mechanism (see Fig. 1) 
32
. 
Of these degradation products, ferulic acid and feruloyl methane are produced from the 
alkaline hydrolysis of the diketone group 
32
, and feruloyl methane can be hydrolyzed 
further to generate vanillin 
31
.
 
Figure 1: The hydrolytic degradation pathway of curcumin. In the presence of (OH
-
), curcumin can be 
hydrolyzed into several different products, including ferulic acid, feruloyl methane, and vanillin. 
 
 Recent research suggests that the alkaline hydrolysis pathway has a limited 
contribution to curcumin degradation in aqueous buffers. First, the hydrolysis-derived 
products are minor compounds in curcumin degradation products. Wang et al found that 
vanillin, ferulic acid, and feruloyl methane were minor degradation products compared to 
trans-6-(4'-hydroxy-3'-methoxyphenyl)-2,4-dioxo-5-hexenal at 280nm 
29
. Second, the 
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comparative stabilities of curcumin and its analogues (such as dimethoxycurcumin, 
demethoxycurcumin, and didemethoxycurcumin) further support that the hydrolysis 
mechanism is not a major pathway in mediating curcumin degradation. Since the 
curcumin analogues have the same conjugated heptadienedione chain as curcumin; it 
follows that if alkaline hydrolysis mechanism is the primary mediator of curcumin 
degradation, these compounds should have similar stability. However, the analogues are 
much more stable than curcumin 
33,34
: For example, after 1 hour incubation in phosphate 
buffer, HPLC analysis showed that curcumin rapidly degraded, while 
dimethoxycurcumin was very stable 
33
, suggesting that the alkaline hydrolysis 
mechanism has a limited contribution in mediating curcumin degradation. 
1.3 Biology of hydrolysis products 
 Of the aforementioned hydrolysis products, the biological effects of vanillin and 
ferulic acid have been well studied. Both compounds have been shown to have anti-
cancer effects in vitro and in vivo. Some of the other hydrolysis degradation products 
have also been studied, though not to the extent of vanillin and ferulic acid. For example, 
ferulaldehyde has been shown to inhibit inflammatory responses in mice 
35
. In the section 
below, we will discuss the anti-cancer effects and mechanisms of vanillin and ferulic acid. 
1.3.1 Ferulic acid 
 Ferulic acid has been shown to inhibit cancer and inflammation in cell culture models. 
After 24 h treatment, 500-1000 µM ferulic acid suppressed 20-25% of cell proliferation 
in lung, colon and oral cancer cells 
36,37
; after 48 hour treatment, curcumin at a lower dose 
(~30 µM) inhibited approximately 50% and 25% of cellular proliferation in HepG2 
hepatoma cells 
38
 and PC-3 prostate cancer cells, respectively 
39
. Ferulic acid has also 
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been shown to inhibit cell cycle progression and induce apoptosis in cancer cells. At a 
dose of 300-1000 µM, ferulic acid can decrease expression of genes involved in G1 cell 
cycle arrest in PC-3 cells 
39
 and cause G2 arrest in malignant oral cancer cells 
37
. It has 
also been shown to inhibit cellular migration and invasion in cancer and endothelial cells, 
which are critical processes involved in tumor metastasis. A wound healing assay in 
A549 lung cancer cells showed that ferulic acid at 200 µM inhibited ~65% of cell 
migration 
36
. At a dose range of 2.5-10 µM, ferulic acid inhibited fibroblast growth 
factor-1 (FGF1)-induced migration and invasion, as well as expressions of matrix 
metalloproteinase-2 (MMP-2) and MMP-9, in human umbilical vein endothelial cells 
(HUVEC) 
40
. Ferulic acid has also been shown to suppress inflammation: In RAW 264.7 
macrophage cells, ferulic acid inhibited IKK-α/β phosphorylation and subsequent nuclear 
translocation of NF-kB, suggesting that ferulic acid inhibited inflammation by 
suppressing NF-kB pathway 
41
. 
 Animal experiments have also shown the anti-cancer effects of ferulic acid. In an 
azoxymethane (AOM)-induced colon cancer model in F334 rats, continuous oral 
administration of 500 mg/kg ferulic acid reduced aberrant crypt foci formation per colon 
by 30.5% 
42
. In a 7,12-dimethylbenz[a]anthracene (DMBA)-induced breast cancer model 
in Sprague-Dawley rats, oral administration of 40 mg/kg ferulic acid for 1 week before 
DMBA induction and throughout the 16 week experimental period reduced mammary 
cancer incidence by 80% 
43
. In a DMBA-induced skin tumor model in Swiss albino mice, 
oral administration of 40 mg/kg ferulic acid abolished tumor progression 
44
. 
Intraperitoneal injection of 50 mg/kg ferulic acid 1 hour prior to exposure to UV light 
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decreased tumor number and volume by 66% and 80% respectively in Swiss albino mice 
45
.  
 However, the biological activities of ferulic acid are less potent compared to 
curcumin. For example, curcumin has been shown to be >160-fold more potent in 
inhibiting cellular proliferation of human peripheral blood mononuclear cells 
46
. In 
addition, ferulic acid at a dose range of 100-1000 µM did not have any effect on cellular 
proliferation of MDA-MB-231 breast cancer cells, while curcumin at a dose as low as 30 
µM inhibited ~50% of MDA-MB-231 proliferation 
47
. In a 12-O-tetradecanoylphorbol-
13-acetate (TPA)-induced skin cancer model in CD-1 mice, topical application of 10 µM 
suppressed the number of skin tumors by 98%, whereas at the same dose ferulic acid only 
caused a 35% inhibition 
48
. In a mouse edema inflammation model, topical application of 
1 µM curcumin almost abolished TPA-induced inflammation, while ferulic acid at the 
same dose only caused a 16% inhibition 
49
. Many other studies have also shown that 
ferulic acid was dramatically less active compared with curcumin 
49-52
.  
1.3.2 Vanillin 
 Similar to ferulic acid, vanillin has also been shown to have anti-cancer and anti-
inflammatory effects. However, the doses of vanillin used in these studies were far higher 
than the amount that would be found as a curcumin degradation product. For example, 
HepG2 in remained viable at concentrations as high as 10 mM 
53
. In other words, as a 
degradation product, vanillin would not be in a biologically relevant concentration that 
could induce anti-cancer or anti-inflammatory effects. Despite this setback, vanillin 
nevertheless has been found to have some biological effects, provided that high doses 
were used.  
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 Vanillin has been shown to modulate cell cycle, and apoptosis in several different cell 
lines, albeit at high doses. For example, the compound has been shown to modulate cell 
cycle by inducing G1 and G2 arrest in HT-29 cells 
54
, downregulating genes associated 
with cell cycle such as cyclin A2 in HepG2 cells 
53
, and by increasing expression of p21, 
a protein that inhibits cyclin B and leads to G2 arrest 
55
. Vanillin also induced apoptosis 
in HT-29 cells 
54
 and further sensitized HeLa cervical cancer cells to tumor necrosis 
factor-related apoptosis-inducing ligand (TRAIL), a cytokine that that is capable of 
inducing apoptosis in cancer cell lines 
56
. In the same cell line, vanillin enhanced 
cleavage of caspase-3 and PARP, both of which are apoptotic proteins that are activated 
by cleavage 
56
. 
 Vanillin is also capable of attenuating cancer metastasis by modulating angiogenesis, 
cell invasion and migration in vitro. In A549 lung cancer, 4T1 mammary adenocarcinoma, 
and HepG2 hepatocarcinoma cells, vanillin was found to decrease cell invasion and 
migration at a dose range of 0.5-1 mM without affecting cell viability 
57-59
; vanillin also 
suppressed angiogenic activity in A549 cells 
57
. Vanillin inhibited metastasis through 
suppressing MMP-9 and phosphoinositide 3-kinase (PI3K)/Akt pathway, which play 
critical roles in cell migration 
59
.  
 In addition to its anti-cancer effects, vanillin has also been shown to have anti-
inflammatory effects. In a dose range of 100-500 µM, vanillin inhibited COX-2 mRNA 
expression in RAW 264.7 mouse macrophage cells stimulated with lipopolysaccharide 
(LPS) 
60
. Like ferulic acid, vanillin suppressed inflammation through the NF-κB pathway. 
In a dose range of 0.25-5 mM, vanillin was shown to inhibit phosphorylation of IκBα in 
9 
 
HepG2 cells 
59
, phosphorylation of p65 in HeLa cells 
56
, and NF-κB binding to the 
consensus sequence in RAW 264.7 cells 
60
.  
 Despite vanillin’s potential as an anti-cancer and anti-inflammatory agent, even when 
compared to ferulic acid, the concentration of vanillin required in the studies were often 
in the millimolar range, while the dosage used for ferulic acid was generally lower; since 
ferulic acid has been shown to be biologically less effective than curcumin, it is unlikely 
that vanillin contributes to the biological effects of curcumin. Indeed, the IC50 for vanillin 
for suppressing peripheral-blood mononuclear cell (PBMC) proliferation was 260 times 
higher than that curcumin 
46
. Curcumin at a dose of 30µM inhibited proliferation of 
human breast cancer MDA-MB-231 cells by 50%, while vanillin was unable to inhibit 
proliferation of the same cell line, even at a dose as high as 1 mM 
47
. 
1.4 Chemistry of autoxidation products of curucmin 
 Griesser et al. found that besides alkaline hydrolysis, curcumin can also be degraded 
via an autoxidation process 
28
. The autoxidation process was pH-dependent with the 
highest rate at pH = 8, which was consistent with a previous study 
29
. During this process, 
equimolar amount of oxygen was consumed to degrade curcumin, suggesting that an 
oxidation reaction is involved in curcumin degradation 
28
. Co-addition of COX-2 enzyme 
accelerated curcumin degradation, and co-addition of hydrogen peroxide further 
increased COX-2-mediated curcumin degradation 
28
. 
 Structural analysis of the autoxidation products have shown that the most abundant 
degradation product was bicyclopentadione, which has incorporated two oxygen atoms 
into the structure of curcumin, consistent with the stoichiometric consumption of oxygen 
10 
 
in curcumin degradation 
28
. Further structural analysis of other degradation products 
suggests that curcumin degradation in aqueous buffer could happen through a mechanism 
comparable to that of lipid peroxidation. The first step of curcumin degradation is the 
hydrogen dissociation from the phenolic group to form a phenolic radical, which then 
migrates to the conjugated heptadienedione chain and leads to the formation of cyclized 
compounds such as bicyclopentadione derivatives of curcumin 
27,28,30
. The radical can 
then be transferred to another curcumin molecule, resulting in a chain reaction that causes 
curcumin to rapidly degrade 
30
. 
 Recent research further suggests that this autoxidation mechanism is the major 
pathway in mediating curcumin degradation 
33
. It was recently shown that a wide range 
of redox-active antioxidants with diverse structures, including gallic acid, ascorbate 
(vitamin C), tert-butylhydroquinone (TBHQ), caffeic acid, rosmarinic acid, and Trolox (a 
water-soluble analogue of vitamin E), dramatically enhanced curcumin stability in 
aqueous buffer, supporting the hypothesis that the autoxidation pathway is the major 
process mediating curcumin degradation. Antioxidant could also enhance curcumin 
stability in vivo: when mice were treated with both curcumin and TBHQ for one hour, the 
amount of curcumin present in plasma was approximately 4-times higher compared to 
that treated with curcumin alone 
33
. As an antioxidant itself, curcumin can scavenge free 
radicals by donating an electron to the free radical, thus becoming a stable radical itself 
61-63
. Antioxidants themselves can be stabilized by other antioxidants if the electron-
donating potential of one of the them is higher than the other 
64
. The electrochemical 
potential of curcumin has been reported as 0.66V 
65
; comparatively, the electrochemical 
potential of antioxidants such as ascorbate, Trolox, and caffeic acid have been reported as 
11 
 
0.282V 
64
, 0.48V 
64
, and 0.45V 
66
 respectively. In other words, the aforementioned 
antioxidants are able to stabilize curcumin due to their higher electron-donating potential.  
 Structure and activity relationship study showed that several structural moieties of 
curcumin are critical for curcumin stability. These structural moieties include: (1) the 
phenolic group: previous studies have shown that dimethoxycurcumin, in which the 
radical-initiating phenolic (-OH) groups are converted to methoxy groups (-OCH3), was 
highly stable in aqueous buffer, cultured cells and animals 
30,33
, suggesting the critical 
role of the phenolic group in curcumin stability. Indeed, only ~20% of 
dimethoxycurcumin dissolved in phosphate buffer degraded after 60 minutes, whereas 
curcumin had already degraded by 80% within the first 10 minutes 
33
. In addition, several 
studies have shown that dimethoxycurcumin exerts more potent anti-proliferative and 
anti-inflammatory effects compared to curcumin 
67-69
. The enhanced stability of 
dimethoxycurcumin can be explained by the autoxidation mechanism: since the hydrogen 
dissociation from the phenolic group to form a phenolic radical is the first step to initiate 
curcumin degradation, blocking this group would dramatically enhance curcumin 
stability; (2) ortho-substitution of phenolic group: recent research has shown that the 
ortho-substitution groups also play important roles in curcumin stability, though more 
studies are needed to clarify the structure and activity relationship. For example, 
demethoxycurcumin, in which the ortho-substitution group is changed from methoxy to 
hydrogen, showed dramatically enhanced stability compared to curcumin 
30,34
. This can 
also be explained by the autoxidation mechanism: as discussed earlier, the first step of 
curcumin degradation is the formation of the phenolic radical (Ph-O
●
), and the rate of p 
radical formation is dependent on the bond dissociation energy of the phenol group (Ph-
12 
 
OH), which is affected by the electron-donating properties of the substitution groups on 
the aromatic ring 
70
. Compared to hydrogen, methoxy group has stronger electron-
donating properties; therefore, curcumin, which possess an ortho-substitution of methoxy 
group, will generate the phenolic radical more easily than demethoxycurcumin. The same 
mechanism can also explain the enhanced stability of bisdemethoxycurcumin compared 
to curcumin 
34
; (3) the conjugated heptadienedione chain: previous studies have shown 
that tetrahydrocurcumin, in which the carbon-carbon double bonds in the conjugated 
heptadienedione chain were reduced to single bonds, has enhanced stability compared to 
curcumin 
71
. This enhanced stability could also be explained by the autoxidation 
mechanism, as structural changes of the heptadienedione chain block the radical 
migration and subsequent formation of bicyclopentadione derivatives of curcumin. 
Together, these structure and activity relationship studies could help us to better 
understand the mechanism of curcumin stability, leading to design of better curcumin-
based therapeutics. 
1.5 Biology of autoxidation products of curcumin 
 To date, the biological activities of the curcumin oxidation products are largely 
unknown. Ketron et al have suggested that the reactive intermediates generated during 
curcumin degradation could increase topoisomerase II-mediated DNA cleavage 
72
. 
Topoisomerase II is an enzyme responsible for preventing under- or over-winding of 
DNA during replication by covalently binding to the double stranded DNA, cleaving both 
strands, unwinding them, and finally ligating them. Ketron et al found that treatment with 
curcumin alone or potassium ferricyanide alone could not enhance topoisomerase II 
mediated-DNA cleavage; however, their combination enhanced DNA cleavage in a dose-
13 
 
dependent manner. The stable degradation product of curcumin bicyclopentadione itself 
had little effect on DNA cleavage with or without the presence of potassium ferricyanide 
72
. Together, these results indicate that the reactive intermediates formed during curcumin 
degradation, such as the quinone methide radical intermediates, could contribute to the 
topoisomerase II-induced DNA cleavage 
72
. 
 If curcumin oxidation products, but not the parent compound, were the cause of 
curcumin’s biological efficacy, it follows that if curcumin degradation was suppressed, 
the biological activities of curcumin would be attenuated. However, a recent study did 
not support this hypothesis. Instead, the results showed that when curcumin degradation 
was suppressed through co-addition of serum or antioxidants, the biological activities of 
curcumin were dramatically enhanced 
29
. These results suggest that curcumin, but not its 
degradation products, have potent biological activities. Further studies are needed to 
better characterize the role of autoxidation in the biological activities of curcumin. 
1.6 Conclusion 
 Although curcumin has been shown to have anti-cancer and anti-inflammatory effects, 
the compound has been hampered by the lack of metabolic and chemical stability. In 
alkaline aqueous solutions, curcumin can undergo hydrolysis and oxidation. Through the 
hydrolysis pathway, curcumin degrades into hydrolysis products such as vanillin, ferulic 
acid, ferualdehyde, and feruloylmethane. Through autoxidation, curcumin forms a 
phenolic radical that incorporates oxygen into the reaction; one of the final products is 
bicyclopentadione 
28
. Based on evidence from the current literature, curcumin most likely 
degrades through oxidation rather than through hydrolysis.  
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 The evidence for the oxidative pathway lies in the evidence from structurally similar 
curcumin analogues and the stabilizing effects of antioxidants on curcumin. If curcumin 
degraded primarily through hydrolysis, the functional phenolic group would have little 
effect on the stability of curcumin, since hydrolysis occurs on the diketone group on the 
heptadioenone bridge; however, data from curcumin analogue studies show that the 
phenolic functional groups greatly affect stability. Furthermore, curcumin can be 
stabilized by other antioxidants in basal media. If hydrolysis was the primary degradation 
pathway, antioxidants would have little effect on curcumin’s stability since during 
hydrolysis curcumin does not form radicals. 
 Because curcumin autoxidation is a recent discovery, the biology of autoxidation 
products of remains poorly characterized. It has been suggested that curcumin exerted its 
effects through its oxidative intermediates such as its quinone methides 
72
. However, 
when curcumin is stabilized through co-addition of serum or antioxidants, the biological 
activities of curcumin were greatly enhanced, suggesting that curcumin, but not its 
degradation products, has potent biological activities 
33
 .  
 In conclusion, emerging research supports the hypothesis that the autoxidation 
pathway is the major mechanism mediating curcumin degradation, but further studies are 
needed to characterize the roles of autoxidation in the biological effects of curcumin. In 
next chapter, the biological activities and mechanisms of the oxidative degradation 
products of curcumin will be examined. 
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CHAPTER 2 
CURCUMIN, BUT NOT ITS OXIDATIVE DEGRADATION PRODUCTS, 
ATTENUATES INFLAMMATORY RESPONSES AND NF-kB SIGNALING 
2.1 Introduction 
 Curcumin can autoxidize to bicyclopentadione at physiological pH 
30
. To date, there 
is little literature on the biological activity of curcumin oxidation products. Ketron et al 
found that curcumin alone did not increase topoisomerase II-mediated DNA cleavage, but 
when a potassium ferricyanide, a Fe
3+
 source, was added to curcumin, DNA cleavage 
occurred. The associated DNA cleavage corresponded with a decrease in curcumin's peak 
at 430nm and an increase in the oxidation products peak at 263nm. Since 
bicyclopentadione, one of the major oxidation products, had little effect on DNA 
cleavage regardless of whether Fe
3+
 was present, Ketron et al concluded that the DNA 
cleavage was caused by curcumin oxidation intermediates 
72
. However Nimiya et al 
reported that curcumin is stabilized by the presence of another antioxidant, leading to 
enhanced anti-proliferative activities on MC38 colon cancer cells in free media 
33
. 
Antioxidants such as ascorbic acid would stabilize the curcumin radical, which would 
otherwise undergo autoxidation. In other words, the study suggests that the biology of 
curcumin does not come from the oxidative degradation products. 
 Due to the conflicting data on the biology of curcumin oxidative degradation products, 
further studies must be conducted to elucidate their effects. To date, there have been no 
studies on the effects of curcumin’s oxidative degradation products on inflammation. 
Thus, the objective of this study was to compare the effects of these products to curcumin 
16 
 
in terms of inflammation, and to provide further insight on biology of the degradation 
products.  
2.2 Materials and Methods 
2.2.1 Curcumin degradation products and cell culture 
 Curcumin was chemically synthesized in the laboratory. Total degradation products 
of curcumin (TDP) were obtained by incubating curcumin in pH 7.4 phosphate buffer and 
extracting them with ethyl acetate. Bicyclopentadione (BCPD) was isolated from the total 
degradation products. RAW 264.7 murine macrophage cells were maintained in 
Dulbecco’s modified Eagle medium (DMEM, Lonza, Allendale, NJ) supplemented with 
10% fetal bovine serum (Corning Inc, Corning, New York) and antibiotics (100 U/mL 
penicillin and 100 μg/mL streptomycin, Lonza, Allendale, NJ) in a 37ºC incubator with 5% 
CO2.  
2.2.2 Nitric oxide measurement and cell viability 
 RAW 264.7 cells were seeded into 96-well plates in complete medium (DMEM that 
containing 10% fetal bovine serum) After 24 hour incubation, cells were treated with test 
compounds and 0.5 μg/mL LPS. After another 24 hours, cell medium was transferred into 
another 96-well plate and an equal volume of Griess reagent (0.1% NED, 1% 
sulfanilamide, 4% phosphoric acid) was added to the cell medium. The absorbance was 
read at 540 nm. Cell proliferation was assessed by 3-(4,5-dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide (MTT) assay. 
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2.2.3 Sample preparation for iNOS and COX-2 Western blots 
 RAW 264.7 cells were seeded in 6-well plates for 24 hours in complete medium. 
After 24 hour incubation, cells were treated with the test compounds and 0.5 μg/mL LPS. 
After another 24 hours, the medium was decanted and the cells were washed with ice-
cold PBS and lysed with RIPA buffer containing phosphatase inhibitors and 1 mM 
EDTA. The total protein in the lysates was quantified using a BCA kit (Thermo-
Scientific, Waltham, MA). Laemli loading buffer (Amresco, Solon, OH) was added into 
all samples, which were stored at-20ºC until ready for use. 
2.2.4 Sample preparation for IκBα and p-IKK Western blots 
 RAW 264.7 cells were seeded in 6 well plates for 24 hours in complete medium. 
Cells were pre-treated with either the test compounds or DMSO vehicle for 1.5 hours. 
The cells were then treated with 0.5 μg/mL LPS for 20 minutes. Samples were collected 
according to the procedure described above. 
2.2.5 Sample preparation for NF-κB translocation 
 RAW 264.7 cells were seeded into 60mm plates for 24 hours in complete medium. 
Cells were pre-treated with either the test compound or DMSO vehicle for 1.5 hours. The 
cells were then treated with 2 μg/mL LPS for 30 minutes. The nuclear extracts were 
collected using nuclear extraction kit (Cayman Chemicals, Ann Arbor, MI) according to 
the manufacturer’s instructions (a modification was to wash the nuclear pellet with ice-
cold phosphate saline buffer 3 times and centrifuging the suspension at 4500 g between 
each wash).  
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2.2.6 Western Blotting 
 Equal amounts of protein were resolved with 8% SDS-PAGE gel and transferred onto 
nitrocellulose membrane. The membrane was washed with TBS, blocked with 5% bovine 
serum albumin, incubated with the primary antibodies, and rocked gently at 4ºC 
overnight. After primary incubation, membranes were washed with TBS containing 
0.05% TWEEN before probing with LI-COR IRDye 800CW Goat anti-Rabbit and IRDye 
680RD Goat anti-Mouse secondary antibodies at room temperature. Membranes were 
washed again and scanned with the Odyssey imaging system (LICOR, Lincoln, NE). 
Western blot signal quantification was performed in ImageJ. Cytoplasmic protein signals 
were normalized with the β-actin signal, while the nuclear protein signals were 
normalized with the lamin signals. The following primary antibodies were used: anti-
iNOS, anti-COX-2, anti-IκBα, anti-p-IKK, anti-NF-κB p65 (Cell Signaling, Danvers, 
MA), anti- β-actin (Sigma, St. Louis, MO), and anti-lamin A/C (Santa Cruz, Dallas, TX). 
Anti-Hsp90 (Santa Cruz, Dallas, TX) was used to check for contamination in the nuclear 
fraction.  
2.2.7 Statistical Analysis 
 All results are expressed as mean  standard deviation (S.D.). All statistical 
calculations were performed using ANOVA followed by Tukey’s test with the assistance 
of the R statistical software. If a significant difference among the interaction between 
treatment and dose was found, the interaction was separated by either treatment or dose 
and analyzed again with ANOVA followed by Tukey’s. Statistical significance was 
considered significant at p<0.05. Results are from 3 independent experiments.  
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2.3 Results 
2.3.1 Curcumin, not its degradation products, attenuates LPS-induced nitric oxide 
production 
 Under inflammatory conditions, nitric oxide is synthesized, and curcumin is a known 
nitric oxide inhibitor 
73
. In this experiment, the comparative effects of curcumin, TDP, 
and BCPD on LPS-induced nitric oxide production in RAW 264.7 were examined. The 
cells were treated with these test compounds at several different doses in combination 
with LPS for 24 hours. Since there was a significant difference among the interaction of 
treatment and dose, the interaction was separated by dose to determine the effect of the 
treatment. Curcumin significantly decreased LPS-induced nitric oxide production, which 
is consistent with previous reports 
73
. TDP also showed a slight dose-dependent decrease 
in nitric oxide production. On the other hand, treatment with BCPD did not decrease 
nitric oxide production (Fig. 2). 
2.3.2 Curcumin, but not its degradation products, inhibits LPS-induced iNOS 
expression 
 Because nitric oxide is produced from iNOS under inflammatory conditions 
74
, the 
comparative effects of curcumin, TDP and BCPD on iNOS expression were examined 
(Figure 3). Since there was a significant difference among the interaction of treatment 
and dose, the interaction was partitioned by treatment to determine the effect of the 
treatment dose on iNOS expression. Starting from 3.68 μg/mL, curcumin significantly 
inhibits iNOS expression in RAW 264.7 cells stimulated with LPS, consistent with 
previous reports 
75
. TDP appeared to have a small dose-dependent effect on iNOS 
inhibition, while BCPD failed to significantly inhibit iNOS expression regardless of dose. 
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Figure 2: The effects of curcumin, TDP, and BCPD on LPS-induced nitric oxide production. 
Concentration of nitric oxide in medium was calculated as the fraction of the absorbance of the 
treatment over the absorbance of the LPS control. Results are represented as meansS.D from three 
independent experiments. A significant difference among interaction of treatment and dose 
concentration was found, so the interaction was separated by dose to examine the effect of the 
treatment at given certain dose. * indicates significance from the LPS only control at p<0.05. Different 
letters indicate significant difference between the treatments at the given concentration (p<0.05). 
2.3.3 Curcumin, but not its degradation products, inhibits LPS-induced COX-2 
expression 
 Like iNOS, COX-2 is another protein that is produced under inflammatory conditions. 
To examine the comparative effects of curcumin and the oxidative degradation products 
on COX-2 expression, RAW-264.7 cells were treated with 0.5 μg/mL LPS and 9.2 μg/mL 
of curcumin, TDP, or BCPD for 24 hours. COX-2 expression was then examined with 
Western blotting (Figure 4). Curcumin greatly inhibited COX-2 expression, consistent 
with previous reports 
75
; however, neither the TDP nor BCPD significantly inhibited 
COX-2 expression. 
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Figure 3: The effects of curcumin, TDP, and BCPD on iNOS expression. 
 RAW 264.7 cells were treated with test compound and 0.5 μg/mL LPS for 24 hours, iNOS expression 
was analyzed by Western blotting (A). iNOS signals were normalized with the β-actin signals and the 
intensity was calculated as the fraction of the averaged normalized LPS signal. Results are represented 
as meansS.D from three independent experiments (B). Since there was a significant difference in the 
interaction of treatment and dose, the interaction was separated by dose to examine the effect of 
treatment at a given dose. * indicates significance from the LPS-only control at p<0.05. Different 
letters indicate significant differences between the groups at the given dose at p<0.05. 
2.3.4 Curcumin, but not its degradation products, inhibits LPS-induced p65 
translocation 
 Both iNOS and COX-2 are produced when the NF-κB pathway is activated 76. Under 
inflammatory conditions, the NF-κB dimer translocates into the nucleus and initiates the 
transcription of many inflammatory mediators such as iNOS and COX-2 
77
. Curcumin is 
known to inhibit translocation of NF-κB 78,79. To assess the ability of curcumin’s 
degradation products to inhibit NF-κB translocation, RAW 264.7 cells were pre-treated 
with 36.2 μg/mL of test compound for 1.5 hours, followed by a 30 minute induction of 
inflammation with 2 μg/mL LPS. The nuclear fraction was collected and subjected to 
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Western blotting. Curcumin inhibited the translocation of p65 into the nucleus, which is 
consistent with previous reports 
79
; neither total degradation products nor 
bicyclopentadione significantly inhibited the protein’s translocation. 
 
Figure 4: The effects of curcumin, TDP, and BCPD on COX-2 expression  
RAW 264.7 cells were incubated with 0.5 μg/mL LPS and 9.2 μg/mL of each test compound for 24 
hours, COX-2 expression was analyzed by Western blotting (A). COX-2 signals were normalized with 
the β-actin signals and the intensity was calculated as the fraction of the averaged LPS signal. Results 
are represented as meansS.D from three independent experiments (B). Different letters indicate 
significant difference between the groups at p<0.05  
2.3.5 Curcumin, but not its degradation products, inhibits LPS-induced IκBα 
degradation and IKK phosphorylation 
 Upstream of NF-κB nuclear translocation are the proteins IκBα and IκB kinase (IKK). 
IκBα is responsible for sequestering NF-κB in the cytoplasm; under inflammatory 
conditions, IκBα is phosphorylated by IKK and is sent for degradation. IKK itself is  
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Figure 5: The effects of curcumin, TDP, and BCPD on NF-κB (p65) nuclear translocation.  
RAW 264.7 cells were pre-treated with 36.2 μg/mL test compound or DMSO vehicle for 1.5 hours, 
and then stimulated with 2 μg/mL LPS for 30 min. The nuclear fraction was collected and subjected to 
Western blotting (A). p65 signals were normalized with the lamin signals and the intensity was 
calculated as the fraction of the LPS only signal. Results are represented as meansS.D from three 
independent experiments (B). Different letters indicate significant difference between the groups at 
p<0.05. 
also activated by phosphorylation. Curcumin is known to modulate the NF-κB pathway 
by inhibiting degradation of IκBα and phosphorylation of IKK 79. To assess the effects of 
curcumin’s oxidative degradation products on these two proteins, RAW 264.7 cells were 
pre-treated with 36.2 μg/mL of curcumin, TDP, or BCPD for 1.5 hours, followed by 20 
minute stimulation of 0.5 μg/mL LPS; the cell lysate was collected and subjected to 
Western blotting (Figures 6-7). Curcumin rescued IκBα from degradation during LPS-
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induced inflammation, whereas neither TDP nor BCPD significantly inhibited its 
degradation. Additionally, curcumin inhibited phosphorylation of IKK, whereas neither 
TDP nor BCPD significantly inhibited IKK phosphorylation 
 
Figure 6: The effects of curcumin, TDP, and BCPD on IκBα degradation. 
RAW 264.7 cells were pre-treated with incubated 36.8 μg/mL test compound for 1.5 hours followed 
by 0.5 µg/mL LPS stimulation for 30 minutes. IκBα signals were normalized with the β-actin signals. 
Relative intensity was calculated as the fraction of the DMSO (No LPS) control. Results are 
represented as meansS.D from three independent experiments (B). Different letters indicate 
significant difference between the groups at p<0.05 
2.4 Discussion  
 The results of this study further support that curcumin, but not its oxidative 
degradation products, is biologically active. Curcumin is known for its anti-inflammatory  
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Figure 7: The effects of curcumin, TDP, and BCPD on IKK phosphorylation. 
RAW 264.7 cells were pre-treated with incubated 36.8 μg/mL of each treatment for 1.5 hours 
followed by 0.5 μg/mL LPS stimulation for 30 minutes (A). IKK signals were normalized with the 
actin signal. IKK phosphorylation intensity was calculated as the fraction of the LPS control. Results 
are represented as meansS.D from three independent experiments (B). Different letters indicate 
significant difference between the groups at p<0.05. 
effects via the NF-κB pathway, and the results for curcumin are consistent with previous 
studies 
73,78,79
. On the other hand, neither TDP nor BCPD was as effective in inhibiting 
nitric oxide production, iNOS and COX-2 expression, translocation of p65 into the 
nucleus, and NF-κB pathway proteins upstream of p65 translocation. Total degradation 
products showed a slight dose-dependent decrease in both nitric oxide production and 
iNOS expression, but did not inhibit expression of COX-2, degradation of IκBα, 
phosphorylation of IKK, and translocation of p65. The slight dose-dependent decrease 
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may be attributed to the residual curcumin that may have been present in the degradation 
mixture. BCPD showed no significant effect in all the experiments performed. Although 
high doses of each test compound were used for the NF-κB experiments, the results 
nevertheless suggest curcumin is more biologically active than the oxidation products.  
 In conclusion, curcumin’s oxidative degradation products, particularly 
bicyclopentadione, have little anti-inflammatory effect compared to curcumin. Further 
research should be conducted to examine the role of curcumin oxidative degradation 
products in other biological models.  
  
A) 
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APPENDIX A 
EFFECT OF TRICLOCARBAN ON ANIMAL BODY WEIGHT 
 The consumption of polyunsaturated omega-6 fatty acid is high in the Western world 
due to the use of vegetable oil, which contains linoleic acid. On the other hand, omega-3 
fatty acid intake is low in the Western world, and some studies have shown a correlation 
between high omega-6 to omega-3 ratio and obesity. In obese mothers, the ratio of 
omega-6 to omega-3 fatty acid in breast milk was greater than in normal-weight mothers 
80
. Omega-6 fatty acids can be metabolized through the cytochrome P450 epoxygenase 
pathway. First, the omega-6 arachidonic acid is metabolized by epxoygenase to form 
epoxyeicosatrienoic acids (EET), which are quickly metabolized by soluble epoxide 
hydrolase (sEH) 
81
. Blocking this enzyme increases tissue levels of EET, which may have 
pro-obesity effects (unpublished results).  
 Triclocarban is an antibacterial agent used in personal care products such as hand 
soaps. It has been found in human urine, raising concerns about the potential hazards of 
continuous exposure to this bacteriocide 
82
. Schebb et al found that after a regular shower 
using triclocarban-containing soaps, micromolar amounts of the compound could be 
detected in the urine; furthermore, topical application of triclocarban was sufficient to 
block sEH activity in mice 
83
. In other words, triclocarban may promote obesity by 
increasing the concentration of EET, which is derived from omega-6 fatty acids. Based 
on the available results, it is hypothesized that triclocarban promotes obesity by 
increasing concentration of EET. 
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 The first objective was to compare the weights of mice fed with 0.08% triclocarban 
together with 10% corn oil compared to mice fed with 10% corn oil alone. Mice weight 
was recorded twice a week for 6 weeks. Food intake was monitored and food was 
changed twice per week. Student t-test was utilized to determine significant difference 
between the two groups for each day the weights of the mice were recorded. However, 
mice that were fed 0.08% triclocarban together with 10% corn oil gained weight more 
slowly than mice fed with corn oil alone, thus contradicting our hypothesis (Figure 8). It 
is likely that the dose of triclocarban used in this experiment induced toxicity effects in 
the mice, leading to the loss in weight. 
 
Figure 8: Weights of mice fed with 10% corn oil alone (Control) or with 10% corn oil supplemented 
with 0.08% triclocarban (TCC). Student t-test was performed between the groups for each pair of data 
point (p<0.05). 
  
* * 
* 
* 
* * 
* 
15
17
19
21
23
25
27
29
0 10 20 30 40
W
e
ig
h
t 
(g
) 
Day 
Control
TCC
29 
 
APPENDIX B 
COMPARATIVE STABILITY OF CURCUMIN, DIDEMETHYLCURCUMIN, 
AND DIMETHOXYCURCUMIN, AND THEIR EFFECTS ON NITRIC OXIDE 
PRODUCTION 
 Although curcumin has been reported for its numerous health benefits, it is also 
metabolically unstable. Furthermore, in buffers at physiological pH, curcumin degrades 
rapidly 
29
. Due to its instability, there is a need for a stable curcumin analogue that is as 
effective as curcumin. Recent data have suggested that methoxylating or hydroxylating 
the functional groups on curcumin’s phenolic rings may affect curcumin activity. For 
example, didemethylcurcumin (a curcumin analogue where all methoxy groups were 
replaced with hydroxyl groups) showed higher antioxidant activity than curcumin, 
whereas whereas dimethoxycurcumin (an analogue where all hydroxyl groups were 
replaced with hydroxyl groups) showed no antioxidant effect 
84
. The result suggests a 
possible structure relationship between the functional groups found on the curcumin’s 
benzene rings and the activity of the curcumin or its analogue. While the effects of 
curcumin have been compared with either didemethylcurcumin or dimethoxycurcumin in 
several biological studies 
67-69,85-88
, no systematic biological study has been done on the 
structural relationship activity of both analogues compared to curcumin. Here, the 
comparative effects of curcumin and the two analogues on nitric oxide production were 
examined. Additionally, HPLC analysis of intracellular curcumin and its analogues was 
also conducted to examine the stability of each compound within the cells after treatment. 
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 RAW 264.7 cells were seeded in complete media and were treated with varying doses 
of curcumin, didemethylcurcumin, or dimethoxycurcumin, with or without 0.5 μg/mL 
LPS. Nitric oxide measurement was performed as described in Materials and Methods in 
Chapter 2. For HPLC analysis, cells were treated with 20 μM of each treatment 
compound without LPS stimulation; after 24 or 48 hours of incubation, the medium was 
removed. Plates were rinsed with ice-cold PBS, and cells were lysed with RIPA buffer to 
release intracellular treatment compounds. 
 
Figure 9: Nitric oxide production dose response at 24 hours (A) and 48 hours (B) for all treatments. 
At 48 hours, there was a significant difference among the treatments at 6.25μM and 12.5μM (C). 
Different letters indicated significance (p<0.05). 
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Ethyl acetate was used to extract the treatments from the buffer and was evaporated in a 
vacuum centrifuge. Before HPLC analysis, samples were dissolved in methanol, and 
reverse phase chromatography with a C-18 column was used. Prior to ethyl acetate 
extraction, RIPA buffer was aliquoted to perform the BCA assay (see Materials and 
Methods, Chapter 2). HPLC results were expressed as the weight of each treatment 
compound remaining intracellularly over the total protein weight. Statistical calculations 
were performed using ANOVA followed by the Tukey test with the assistance of the R 
statistical software. 
 
Figure 10: HPLC analysis of didemethylcurcumin (A), curcumin (B), and dimethoxycurcumin (C). 
For each compound, the top chart shows the peak of their respective standards, while the bottom chart 
shows the peaks of the compound after cells were treated for 24 or 48 hours with the compounds. (D) 
shows the amount of intracellular compound found in the RAW 264.7 cells at each time point; 
didemethylcurcumin was below the range of detection at both times. Different letters indicate 
significant differences (p<0.05) 
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 The difference in nitric oxide inhibition between each compound was more apparent 
after 48 hours; no significant differences among the compounds were found at each dose 
in the 24 hour treatment (Figure 9). At 6.25 μM, dimethoxycurcumin was more effective 
at inhibiting nitric oxide production than either curcumin or didemethylcurcumin, 
suggesting the critical role of the methoxy functional groups in stabilizing the curcumin 
analogue. Indeed, dimethoxycurcumin was found to be significantly more stable than 
either curcumin or didemethylcurcumin after 24 and 48 hour treatments (Figure 10). On 
the other hand, didemethylcurcumin was below the detection range was at both time 
points, and curcumin's small peak at 24 hours decreased even further after 48 hours. 
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APPENDIX C 
CURCUMIN STABILIZED BY ANTIOXIDANTS CAN ATTENUATE LPS-
INDUCED NITRIC OXIDE PRODUCTION AND iNOS EXPRESSION 
 Curcumin is unstable in serum-free media at physiological pH 
29
; under these 
conditions, curcumin can undergo oxidative degradation 
30
. Recently, Nimiya et al 
discovered that curcumin can be stabilized by the addition of antioxidants 
33
. Details on 
curcumin oxidative degradation can be found in Chapter 1. The objective of this study 
was to compare the anti-inflammatory effects of curcumin dissolved in free media versus 
curcumin co-dissolved with antioxidants in the same media. 
 RAW 264.7 cells were seeded in complete media and were treated with 6.25 μM 
curcumin and/or 2.9 μM of a given antioxidant in serum-free basal medium. 
Inflammation was stimulated with 0.5 μg/mL LPS. Nitric oxide measurement, cell 
viability, and Western blotting were performed as described in the Materials and Methods 
section of chapter 2. For statistical analysis, one-way ANOVA was performed for all 
groups followed by Dunnett’s test. 
 Treatment with curcumin alone or antioxidant alone did not significantly decrease 
LPS-induced nitric oxide production. However, their combination significantly induced 
LPS-induced nitric oxide production (Figure 11). Furthermore, curcumin combined with 
antioxidant significantly decreased LPS-induced iNOS expression (Figure 12). These 
results suggest that the antioxidants increase curcumin’s efficacy by stabilizing curcumin, 
which would otherwise undergo oxidative degradation. 
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Figure 11: Nitric oxide production of LPS-induced RAW 264.7 cells treated with curcumin and/or 
Trolox, sodium ascorbate (SA), caffeic acid (CA), or gallic acid (GA). 
Neither curcumin nor antioxidant alone inhibited nitric oxide production, but both compounds 
synergistically decreased nitric oxide production. Nitrite concentration was calculated as the fraction 
of the absorbance of the LPS only control. Results are expressed as meanS.D. 
 
Figure 12: iNOS expression of LPS-induced RAW 264.7 cells treated with curcumin and/or Trolox, 
sodium ascorbate (SA), caffeic acid (CA), or gallic acid (GA) (B). 
Neither curcumin nor antioxidant alone inhibited iNOS expression, but both compounds 
synergistically decreased nitric oxide production (B). Results are expressed as meanS.D 
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